Florent Dufour
University of Paris
6 Papers
Florent Dufour is an academic researcher from University of Paris. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 3, co-authored 6 publications. Previous affiliations of Florent Dufour include PSL Research University & Curie Institute.
Chat about Author
Papers
A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression.
Jing Liu,Jing Liu,Daniela Ottaviani,Daniela Ottaviani,Meriem Sefta,Meriem Sefta,Céline Desbrousses,Céline Desbrousses,Elodie Chapeaublanc,Elodie Chapeaublanc,Rosario Aschero,Nanor Sirab,Nanor Sirab,Fabiana Lubieniecki,Gabriela Lamas,Laurie Tonon,Catherine Dehainault,Clément Hua,Clément Hua,Paul Fréneaux,Sacha Reichman,Narjesse Karboul,Narjesse Karboul,Anne Biton,Liliana Mirabal-Ortega,Liliana Mirabal-Ortega,Magalie Larcher,Magalie Larcher,Céline Brulard,Céline Brulard,Céline Brulard,Sandrine Arrufat,André Nicolas,Nabila Elarouci,Tatiana Popova,Fariba Nemati,Didier Decaudin,David Gentien,Sylvain Baulande,Odette Mariani,Florent Dufour,Florent Dufour,Sylvain Guibert,Céline Vallot,Livia Lumbroso-Le Rouic,Alexandre Matet,Alexandre Matet,Laurence Desjardins,Guillem Pascual-Pasto,Mariona Suñol,Jaume Català-Mora,Genoveva Correa Llano,Jérôme Couturier,Emmanuel Barillot,Emmanuel Barillot,Paula Schaiquevich,Paula Schaiquevich,Marion Gauthier-Villars,Marion Gauthier-Villars,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Lisa Golmard,Lisa Golmard,Claude Houdayer,Hervé Brisse,Isabelle Bernard-Pierrot,Isabelle Bernard-Pierrot,Eric Letouzé,Alain Viari,Simon Saule,Simon Saule,Xavier Sastre-Garau,François Doz,François Doz,Angel M. Carcaboso,Nathalie Cassoux,Nathalie Cassoux,Celio Pouponnot,Celio Pouponnot,Olivier Goureau,Guillermo Chantada,Aurélien de Reyniès,Isabelle Aerts,Isabelle Aerts,Isabelle Aerts,F. Radvanyi,F. Radvanyi +86 more
TL;DR: In this paper, the existence of two retinoblastoma subtypes was demonstrated using multi-omics data, and two subtypes were identified, one in a cone differentiated state and one more aggressive showing cone dedifferentiation and expressing neuronal markers.
Recurrent activating mutations of PPAR gamma associated with luminal bladder tumors.
Natacha Rochel,Clémentine Krucker,L. Coutos-Thevenot,L. Coutos-Thevenot,Judit Osz,R. Zhang,R. Zhang,R. Zhang,E. Guyon,E. Guyon,W. Zita,S. Vanthong,O.A. Hernandez,Maxime Bourguet,K.A. Badawy,Florent Dufour,Florent Dufour,Carole Peluso-Iltis,S. Heckler-Beji,Annick Dejaegere,Aurélie Kamoun,A. De Reynies,Yann Neuzillet,Yann Neuzillet,Sandra Rebouissou,Sandra Rebouissou,Sandra Rebouissou,Claire Béraud,Hervé Lang,Thierry Massfelder,Yves Allory,Yves Allory,Sarah Cianférani,Roland H. Stote,F. Radvanyi,F. Radvanyi,Isabelle Bernard-Pierrot,Isabelle Bernard-Pierrot +37 more
TL;DR: Genomic alterations of PPARG that lead to pro-tumorigenic PPARγ/RXRα pathway activation in luminal bladder tumors are revealed and may open the way towards alternative options for treatment.
53
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Florent Dufour,Florent Dufour,Linda Silina,Linda Silina,Hélène Neyret-Kahn,Hélène Neyret-Kahn,Aura Moreno-Vega,Aura Moreno-Vega,Clémentine Krucker,Clémentine Krucker,Narjesse Karboul,Narjesse Karboul,Marion Dorland-Galliot,Marion Dorland-Galliot,Pascale Maillé,Elodie Chapeaublanc,Elodie Chapeaublanc,Yves Allory,Yves Allory,Nicolas Stransky,Nicolas Stransky,Hélène Haegel,Thierry Menguy,Vanessa Duong,F. Radvanyi,F. Radvanyi,Isabelle Bernard-Pierrot,Isabelle Bernard-Pierrot +27 more
TL;DR: A preclinical proof of concept for TYRO3 as a potential therapeutic target in bladder cancer is provided, which relies on cell cycle inhibition and apoptosis associated with induction of tumour-suppressive signals.
PPARγ is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities
L. Coutos-Thevenot,L. Coutos-Thevenot,Beji S,Hélène Neyret-Kahn,Hélène Neyret-Kahn,Pippo Q,J. Fontugne,J. Fontugne,Judit Osz,Clémentine Krucker,Clémentine Krucker,Groeneveld Cds,Groeneveld Cds,Florent Dufour,Florent Dufour,Aurélie Kamoun,Ley M,Elodie Chapeaublanc,Elodie Chapeaublanc,Reynies Ad,Lebret T,Yves Allory,Yves Allory,Sarah Cianférani,F. Radvanyi,F. Radvanyi,Natacha Rochel,Isabelle Bernard-Pierrot,Isabelle Bernard-Pierrot +28 more
TL;DR: Genetic, epigenetic and functional evidence of a tumor suppressor role for PPARγ in basal bladder tumors offer new therapeutic opportunities for this subgroup and reinforces the interest in stratified medicine based on tumor molecular subtyping.
5
FGFR3 activating mutations induce luminal-like papillary bladder tumor formation and favor a male gender bias
M. Shi,Aura Moreno-Vega,Aura Moreno-Vega,J. Fontugne,J. Fontugne,X.-Y. Meng,X.-Y. Meng,X.-Y. Meng,Florent Dufour,Florent Dufour,Aurélie Kamoun,Sia Viborg Lindskrog,Audrey Rapinat,C. Dunois-Larde,C. Dunois-Larde,M.-L. Lapage,M.-L. Lapage,Elodie Chapeaublanc,Elodie Chapeaublanc,O. Levrel,T. Lebret,A. Almeida,A. De Reynies,Lars Dyrskjøt,Yves Allory,Yves Allory,F. Radvanyi,F. Radvanyi,Isabelle Bernard-Pierrot,Isabelle Bernard-Pierrot +29 more
TL;DR: In this article, a genetically engineered mouse (GEM) model expressing the most frequent FGFR3 mutation in urothelial cells was developed to study their oncogenic properties in vivo.